ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These agents induce rapid cytogenetic responses (CyR) in the majority of CML patients in chronic phase (CP) 2, but in most cases do not eliminate BCR-ABL transcripts, suggesting persistence of residual disease.